RT Journal Article
T1 B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients.
A1 Mendonça-de-Pontes, Roberia
A1 Flores-Montero, Juan
A1 Sanoja-Flores, Luzalba
A1 Puig, Noemi
A1 Pessoa-de-Magalhães, Roberto J
A1 Corral-Mateos, Alba
A1 Salgado, Anna Beatriz
A1 Garcia-Sanchez, Omar
A1 Perez-Moran, Jose
A1 Mateos, Maria-Victoria
A1 Burgos, Leire
A1 Paiva, Bruno
A1 Te-Marvelde, Jeroen
A1 van-der-Velden, Vincent H J
A1 Aguilar, Carlos
A1 Barez, Abelardo
A1 Garcia-Mateo, Aranzazu
A1 Labrador, Jorge
A1 Leoz, Pilar
A1 Aguilera-Sanz, Carmen
A1 Durie, Brian
A1 van-Dongen, Jacques J M
A1 Maiolino, Angelo
A1 Sobral-da-Costa, Elaine
A1 Orfao, Alberto
K1 B-cell regeneration
K1 hemodilution
K1 immunophenotyping
K1 measurable residual disease
K1 multiple myeloma
AB B-cell regeneration during therapy has been considered as a strong prognostic factor in multiple myeloma (MM). However, the effects of therapy and hemodilution in bone marrow (BM) B-cell recovery have not been systematically evaluated during follow-up. MM (n = 177) and adult (≥50y) healthy donor (HD; n = 14) BM samples were studied by next-generation flow (NGF) to simultaneously assess measurable residual disease (MRD) and residual normal B-cell populations. BM hemodilution was detected in 41 out of 177 (23%) patient samples, leading to lower total B-cell, B-cell precursor (BCP) and normal plasma cell (nPC) counts. Among MM BM, decreased percentages (vs. HD) of BCP, transitional/naïve B-cell (TBC/NBC) and nPC populations were observed at diagnosis. BM BCP increased after induction therapy, whereas TBC/NBC counts remained abnormally low. At day+100 postautologous stem cell transplantation, a greater increase in BCP with recovered TBC/NBC cell numbers but persistently low memory B-cell and nPC counts were found. At the end of therapy, complete response (CR) BM samples showed higher CD19- nPC counts vs. non-CR specimens. MRD positivity was associated with higher BCP and nPC percentages. Hemodilution showed a negative impact on BM B-cell distribution. Different BM B-cell regeneration profiles are present in MM at diagnosis and after therapy with no significant association with patient outcome.
PB MDPI AG
SN 2072-6694
YR 2021
FD 2021-04-03
LK http://hdl.handle.net/10668/17662
UL http://hdl.handle.net/10668/17662
LA en
NO Mendonça de Pontes R, Flores-Montero J, Sanoja-Flores L, Puig N, Pessoa de Magalhães RJ, Corral-Mateos A, et al. B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients. Cancers (Basel). 2021 Apr 3;13(7):1704.
DS RISalud
RD Apr 19, 2025